Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dosage of Ropivacaine for Arthroscopic Knee Surgery
NCT04759742Phase 1Completed
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropivacaine in knee injury. Primary endpoint: Median Effective Dose at 24 hours. Started Mar 2021; status: completed.
02
Drugs
ropivacaine
03
Conditions
knee injury
Beyond the preview
Go deeper on NCT04759742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759742.